Chongqing Zhifei Biological Products (300122.SZ) Receives Approval for Clinical Trial Application of Modified Ankara Vaccinia Virus (MVA) Monkeypox Attenuated Live Vaccine

Chongqing Zhifei Biological Products (300122.SZ): Clinical Trial Application for Recombinant Zoster ZFA01 Adjuvant Vaccine (CHO Cell) Accepted

Chongqing Zhifei Biological Products Subsidiary Gets China Nod for Shingles, Chickenpox Vaccine

Chongqing Zhifei Biological Products (300122.SZ) Receives Acceptance for Clinical Trial Application of Freeze-Dried Varicella Inactivated Vaccine

Chongqing Zhifei Biological Products (300122.SZ) Receives Clinical Trial Approval for Acellular Pertussis-Diphtheria-Tetanus (Component) Combination Vaccine for Adults and Adolescents

Chongqing Zhifei Biological Products Reports Worst Q3 Performance in a Decade Amid Dual Pressures from Failing Agency Model and Weak R&D

Chongqing Zhifei Biological Products Elects Yang Shilong as Employee Representative Director

BRIEF-Zhifei Biological Products' Q3 Net Loss At 601.1 Million Yuan

Chongqing Zhifei Biological Products Says Q3 Net Loss at 601.1 Mln Yuan

RSV Outbreak Drives Surge in Prevention Demand as Companies Race to Capture Infant Market

Chongqing Zhifei Biological Products Faces "Waterloo" After 15 Years: HPV Vaccine Batch Releases Plunge 95%, Agency Dependence Creates 73% Revenue Gap

Tirzepatide Competitor Receives Clinical Trial Approval, Zhifei Biological Shares Surge Over 6% Intraday

Chongqing Zhifei Biological Products Co.,Ltd. (300122.SZ): CA111 Injection Receives Clinical Trial Approval

Vaccine Giant's Fall: Chongqing Zhifei Biological Faces Darkest Hour with 21 Billion Yuan Inventory Burden

Vaccine Distribution Giant Chongqing Zhifei Biological Products Faces Growth Slowdown: H1 Net Loss of 597 Million Yuan, Over 100 Billion Yuan in Accounts Receivable Looms

Chongqing Zhifei Biological Products Swings to Loss in H1 as Revenue Plunges 73%

Chongqing Zhifei Biological Products Reports Semi-Annual Results with Net Loss Increase of 126.72%

BRIEF-Zhifei Biological Products H1 Net Loss At 597.1 Million Yuan

Chongqing Zhifei Biological Products Says H1 Net Loss at 597.1 Mln Yuan

BRIEF-Zhifei Biological Products To Issue Corporate Bond